Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-06-2016 | Case Report

CD56 Negative Aggressive T Cell Large Granular Lymphocytic Leukemia

Authors: Mary Theresa Sylvia, Sajini Elizabeth Jacob, Debdatta Basu, Deepak Amalnath, Tarun Kumar Dutta

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2016

Abstract

T cell large granular lymphocytic leukemia is a clonal proliferation of cytotoxic large granular T cells positive for CD3 and CD8. It is a chronic lymphoproliferative disorder with an indolent course. Therapeutic options include observation and low dose chemotherapy. Rarely, they have an aggressive course. Such cases have expression of NK cell associated antigens like CD56 in the T cells. These cases require more aggressive therapy with acute lymphoblastic leukemia regimens. We report a case of fatal CD56 negative T cell large granular lymphocytic leukemia in a 38 year old lady.

Zhang D, Loughran TP Jr (2012) Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology 2012:652–659PubMed

O’Malley Dennis P (2007) T-cell large granular leukemia and related proliferations. Am J Clin Pathol 127:850–859CrossRefPubMed

Chan WC, Foucar K, Morice WG, Catovsky D (2008) T-cell large granular lymphocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissues, vol 4. IARC Press, Lyon, pp 272–273

Rose MG, Berliner N (2004) T-cell large granular lymphocytic leukemia and related disorders. Oncologist 9:247–258CrossRefPubMed

Morice WG, Kurtin PJ, Tefferi A, Hanson CA (2002) Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood 99:268–274CrossRefPubMed

Weidmann E (2000) Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 14:991–997CrossRefPubMed

Lamy T, Bauer FA, Liu JH, Li YX, Pillemer E, Shahidi H, Gregory SA, Zambello R, Marcolongo R, Semenzato G, Loughran TP (2000) Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice. Br J Haematol 108(4):717–723CrossRefPubMed

Alekshun TJ, Tao J, Sokol L (2007) Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature. Am J Hematol 82:481–485CrossRefPubMed

Falcao RP, Simoes BP, Garcia AB (2000) Aggressive variant of morphologically typical T large granular lymphocytic leukaemia/lymphoma lacking NK cell markers. Acta Haematol 104:110–114CrossRef

10.

Tordjman R, Macintyre E, Emile JF, Valensi F, Ribrag V, Burtin ML, Varet B, Brousse N, Hermine O (1996) Aggressive acute CD3+, CD56− T cell large granular lymphocyte leukemia with two stages of maturation arrest. Leukemia 10(9):1514–1519PubMed

11.

Lundell R, Hartung L, Hill S, Perkins SL, Bahler DW (2005) T-cell large granular lymphocyte leukemias have multiple phenotypic abnormalities involving pan—T-cell antigens and receptors for MHC molecules. Am J Clin Pathol 124:937–946CrossRefPubMed

12.

Gentile TC, Uner AH, Hutchison RE, Wright J, Ben-Ezra J, Russell EC, Loughran TP Jr (1994) CD3+, CD56+ aggressive variant of large granular lymphocyte leukemia. Blood 84(7):2315–2321PubMed

13.

Macon WR, Williams ME, Greer JP, Hammer RD, Glick AD, Collins RD, Cousar JB (1996) Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes. Blood 87:1474–1483PubMed

Title: CD56 Negative Aggressive T Cell Large Granular Lymphocytic Leukemia
Authors: Mary Theresa Sylvia
Sajini Elizabeth Jacob
Debdatta Basu
Deepak Amalnath
Tarun Kumar Dutta
Publication date: 01-06-2016
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-015-0502-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2016

Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha

Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat

Ascites as a Manifestation of GVHD: a Rare Phenomenon

Familial Pelger–Huet Anomaly

New Codanin-1 Gene Mutations in a Italian Patient with Congenital Dyserythropoietic Anemia Type I and Heterozygous Beta-Thalassemia

The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer